Abstract
The effectiveness of Synthetic Salmon Calcitonin (SSCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 5 Pagetic patients during a 6 months course therapy, the results show that intranasal administration does not decrease the activity of SSCT in Paget's disease of bone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
